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AbstrACt
Objective Originator pharmaceutical companies 
prolonging the patent of a medicine prevents rivals’ entry 
to the market and competition. As the entry of generic 
alternatives usually results in price reduction, any delay in 
their entry potentially deprives the National Health Service 
(NHS) of much-needed savings. This study estimates 
the potential cost savings lost to the NHS as a result of 
delayed entry of generic low-dose buprenorphine (LDTB) 
patches in England.
Design Two case scenarios were modelled to determine 
the savings from the entry of generic LDTB Butec only 
between February and August 2016 and the potential 
savings which could have been achieved if all generic 
LDTB patches had entered the market at the same time.
setting The volume of utilisation of branded and generic 
LDTB in UK primary care was derived from the NHS 
business services authority website for prescriptions 
dispensed between February 2015 and January 2018.
Main outcome measures Cost savings associated with 
the entry of generic LDTB.
results The cumulative cost savings from the 
introduction of Butec alone was £0.7 ($0.92) million. The 
model predicted that if all generic buprenorphine entered 
the market at the same time with Butec, they could have 
been achieved a £1.2 ($1.57) million saving. This means 
that approximately £0.5 ($0.65) million savings was lost to 
the NHS over the 6-month time period.
Conclusions The entry of Butec was associated with cost 
savings. We estimated that more cost savings could have 
been achieved if other generic LDTB patches had entered 
the market at the same time to drive competition between 
rivals. Patent protection strategies which delayed the entry 
of multiple generics were responsible for the reduced cost 
savings to the NHS in England.
IntrODuCtIOn
According to the British Pain Society, 43% 
of the UK population are living with chronic 
pain that has lasted for 3 months or longer.1 2 
Chronic pain prevalence increases with age 
to affect over 70% of individuals aged over 
65-year-old, mainly due to arthritis or low 
back pain.2 3 Patients with chronic pain seek 
medical attention in primary care up to five 
times more frequently than others, which 
equates to almost five million primary care 
appointments a year.4 
Low-dose transdermal buprenorphine 
(LDTB) patches are an established and 
cost-effective way of managing chronic pain 
unresponsive to oral analgesics and requires 
continuous release analgesics.3 5
Napp pharmaceuticals have held UK patent 
for the low-dose transdermal controlled 
release buprenorphine ‘BuTrans’ since 
2005.6 In February 2016, this patent expired, 
and the company launched Butec, an iden-
tical version of BuTrans that differed only 
in name and priced competitively in 15% 
less than BuTrans price. At the same time, 
a competitor company (Sandoz) obtained 
market authorisation to launch a generic 
version of LDTB patches (Reletrans).6 The 
originator company claimed to the UK 
patents court a breach of patent on the basis 
that the patent ‘defines a transdermal patch 
comprising of 10% weight buprenorphine 
strengths and limitations of this study
 ► The case scenarios were based on perspective (real) 
data and market reaction to the entry of generic 
medicines.
 ► National Health Service business services authority 
website provides a reliable source for prescriptions 
dispensed in England.
 ► Segmented regression of an interrupted time series 
is regarded as the gold standard in pharmacoepide-
miological studies in such studies.
 ► The case scenario 2 assumed that the market share 
of generics would behave in a similar way to Butec 
in scenario 1.
 ► It is possible that the market share of the various 
products may have reacted differently with the 
availability of multiple generics in February 2016.
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base; 10%–15% wt levulinic acid and ~10% weight oley-
loleate as ingredients in the patches’ manufacture and 
that it would be difficult to determine output values espe-
cially since transdermal systems degraded over time’. 
This claim prevented the launch to market of all other 
generic LDTB patches. In August 2016, the Napp case 
went to appeal and judgement found in favour of Sandoz, 
allowing them to manufacture and market generic LDTB 
patches in competition with BuTrans and Butec patches 
in the UK.6 In September 2016, branded generic LDTB 
patches (non-originator products with a trade name 
produced by a manufacturer not the originator)7 such as 
Reletrans and Panitaz, and non-branded generic LDTB 
patches were launched and thus the market for LDTB 
changed.
The selection of a medication is largely dependent on 
key players in drug therapy decision-makings’ (physi-
cians, clinical pharmacists and formulary committee 
members) prescribing behaviour. Studies have found 
that prescribing behaviour of prescribers are influenced 
by drug relating factors such as efficacy, safety, adminis-
tration and cost and policy-related factors such as medi-
cine inclusion in formularies, prescribing restrictions and 
prescribing guidelines.8–14
At the point of use of healthcare services and pharma-
ceuticals, the English national health system is funded 
through general taxation, such as the UK National Health 
Service (NHS), there is always pressure to remain within 
budget and provide value for money for tax payers.15 
The UK exhibits one of the highest prices for branded 
products and the lowest prices for generics in Europe. In 
UK, the key bases of competition are product portfolio, 
competitive pricing, customer service and marketing 
strategy. Pricing has always been a key competitive tool.16
Generics remain a key element in government strategy 
for the cost-effective provision of medicines through the 
NHS.16 17 Generic prescribing is a standard practice in 
UK. Several factors have led to this practice, accounted 
for 81% of items prescribed in primary care in England 
and helped to achieve £7.1 billion savings since 1976 and 
allowed 490 million more items to be prescribed without 
an increase in total spending.18 19 INN prescribing is 
encouraged at early stages as medical schools in the UK 
are teaching medical students generic prescribing.20 
Another factor is that physicians are encouraged in various 
ways, using both financial and non-financial incentives, to 
prescribe generics (using non-proprietary names), since 
this means community pharmacists dispensing general 
practitioners prescriptions are reimbursed at the lowest 
national drug tariff cost. Financial incentives include, for 
example, physicians’ budgets and budgetary incentives, 
generic prescribing targets with incentives. In budgetary 
incentives, savings achieved by the physicians beyond the 
indicative budget can be used for other purposes such as 
training. Other factors include empowering physicians 
with technology and decision support systems to help 
them prescribe generically (such as generic prescribing 
programmes) and providing them with information via 
national and local cost effective prescribing guidelines 
(eg, NICE guidelines). In addition, prescribing moni-
toring and feedback to improve physicians’ prescribing 
and awareness of medicines costs is also used to encourage 
generic prescribing.17 20 21
The aim of this paper is to understand the impact of 
the 6 months delay in the entry of multiple generic LDTB 
patches on the utilisation of LDTB patches in England 
and estimate any potential savings lost to the NHS.
MethOD
Data source
The study was a retrospective analysis of the utilisation of 
LDTB patches in primary care in England. Primary care 
data on the monthly volume and net ingredient cost of 
medicines were derived from the NHS business services 
authority (NHSBSA) website for prescriptions dispensed 
between February 2015 and January 2018.22 This website 
(database) captured monthly information (drug name, 
dose, quantity, drug tariff price and the total cost) on all 
medicines dispensed by community pharmacies against 
prescriptions issued by general medical practitioners and 
non-medical prescribers (nurses and pharmacists) in 
England. Primary care prices were the drug tariff prices, 
which were the prices that set out by the department 
of health and social care on what pharmacies would be 
reimbursed for the cost of each generic medicine they 
dispense for an NHS prescription (before discounts 
and not including dispensing costs), excluding value-
added tax since medicines supplied against primary care 
prescriptions in the UK are exempt from value-added 
tax. Two case scenarios were modelled, to determine the 
savings from the entry of Butec only between February and 
August 2016, and the potential savings which could have 
been achieved if all generic LDTB patches had entered 
the market at the same time. The average costs per mg of 
different LDTB patches and the estimated savings in anal-
ysis are presented in British pounds and US dollars using 
historical average annual exchange rates corresponding 
to each year in the study (in 2015 £1=$1.51, 2016–2018 
1£=$1.31).23
statistical analysis
Average costs per mg of LDTB
Due to the non-uniform linear price change per mg 
between all strengths of LDTB patches, and the 5 mcg/
hour strength patches was the most frequently prescribed 
strength rather than the 10, 15 and 20 mcg/hour 
strengths, we chose the cost of this strength to determine 
the average cost/mg of LDTB (table 1).
Case 1: Savings from the entry of Butec only
Monthly usage and expenditure on BuTrans and Butec 
between February and August 2016 were taken from the 
NHSBSA website. This total usage was then multiplied 
by the price of BuTrans over the same period (since 
the price of BuTrans did not change before or after the 
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introduction of Butec) to calculate what the expenditure 
would have been without the introduction of Butec. The 
actual cost for both BuTrans and Butec over this period 
was then deducted from this estimated expenditure to 
calculate the actual savings to the NHS as a result of the 
entry of Butec.
Case 2: Forecasted savings if all generic LDTB patches had 
entered the market in February 2016
To estimate the savings that could have been achieved 
if other generic LDTB patches (Reletrans, Panitaz and 
non-branded generic buprenorphine) had entered the 
market at the same time as Butec, a model was built, 
based on generic LDTB market shares. It was assumed 
that the total market shares of these other LDTB patches 
would have changed as for Butec’s entry in 2016, that is, 
1% in February and March, 2% in April, 8% in May, 17% 
in June, 27% in July and 38% in August. In this model, 
the utilisation of each generic was multiplied by their 
actual price in September 2016 to calculate the hypothet-
ical expenditure during the period February to August 
2016. This hypothetical expenditure was then deducted 
from the LDTB patches expenditure in the BuTrans 
only scenario (from Case 1) to calculate the potential 
savings that may have been achieved from the entry of 
all generics at the same time as Butec (Case 2). This 
hypothetical saving (Case 2) was then deducted from 
the actual savings from the entry of Butec (Case 1) to 
calculate the savings lost from the delayed entry of these 
branded generics.
Linear regression
Overall expenditure and utilisation trends were exam-
ined for LDTB patches in primary care over the period 
February 2015– January 2018. Linear regression analyses 
were used with a month as the independent variable and 
overall expenditure or utilisation in milligrams as the 
dependent variable. The regression coefficient values 
were divided by the baseline expenditure or utilisation 
(in February 2015) to calculate the average monthly 
percentage increase or decrease in expenditure or utili-
sation of LDTB patches.
Segmented regression
Segmented regression analysis of interrupted time series 
data was used to examine the impact of the launch of 
generic LDTB patches on the prescribing of the origi-
nator brand BuTrans and to establish when the gradient 
changed, using the method of Wagner et al.24 The effect 
was assessed by two parameters, level (β2 and β4) and 
trend (β3 and β5). The following segmented regression 
analysis equation was applied to each individual study 
outcome measure:
Yt = β0 + β1 * time + β2 * launch of Butec in February 2016 
+ β3 * time after launch of Butec in February 2016 + β4 * 
launch of generic LDTB other than Butec in September 
2016 + β5 * time after launch of generic LDTB other than 
Butec in September 2016 + et
where Yt is the monthly outcome measure. Time was a 
continuous variable referring to time, in months, from 
the start of the observation period, ranging from 1 to 36 
Table 1 Average costs per mg in sterling pounds and US dollars of 5 mcg/hour transdermal buprenorphine patches in 
primary care in England between 2015 and 2018
February 2015–
July 2015
August 2015–
January 2016
February 2016–
July 2016
August 2016–
January 2017
February 2017–
July 2017
August 2017–
January 2018
Average cost/mg
BuTrans £0.788
$1.19
£0.788
$1.19
£0.788
$1.03
£0.788
$1.03
£0.788
$1.03
£0.976
$1.27
Butec – – £0.648
$0.84
£0.355
$0.46
£0.35
$0.45
£0.439
$0.575
Reletrans – – – £0.394
$0.51
£0.394
$0.51
£0.440
$0.576
Panitaz – – – £0.441
$0.57
£0.352
$0.46
£0.365
$0.478
Sevodyne – – – – £0.355
$0.46
£0.439
$0.575
Bupramyl – – – – £0.352
$0.46
£0.385
$0.504
Busiete – – – – – £0.386
$0.505
Non-branded 
generic 
buprenorphine
– – – £0.76
$0.99
£0.76
$0.99
– 
I– indicates the product was not yet marketed.
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from the start to the end of the study period. The launch 
of Butec in February 2016 was a dichotomous variable (0 
before February 2016; 1 since February 2016). Time after 
launch of Butec in February 2016 was a continuous vari-
able beginning in February 2016. β0 and β1 represent the 
intercept and trend over time during the preintervention 
period, respectively. β2 represents the change in the level 
at the time of launch of Butec in February 2016 and β3 
represents the trend change in the slope after launch of 
Butec in February 2016, both compared with those in the 
preintervention period. β4 represents the change in the 
level at the time of launch of generic LDTB other than 
Butec in September 2016 and β5 represents the trend 
change in the slope after launch of generic LDTB other 
than Butec in September 2016. et represents the error 
term. All calculations were performed using Microsoft 
Excel 2013 and STATA MP13.
Patient and public involvement
No patients or members of the public were involved in 
this study.
results
Prices lDtb patches
Between February 2015 and July 2017, the prices of 
BuTrans (originator brand of LDTB) and non-branded 
generic buprenorphine were not changed. Butec patches 
price reduced gradually by 50% over the same time 
period. Prices of Reletrans and Panitaz decreased in a 
similar gradual manner. Post-August 2017, the prices of 
the majority of buprenorphine patches were increased 
(table 1).
utilisation of lDtb patches
Regression analysis indicated that the overall utilisa-
tion of LDTB patches increased significantly (p>0.001) 
by an average of 4.8% per month (95% CI 4.2 to 5.4) 
from 4 981 900 mg in February 2015 to 6 668 540 mg in 
January 2018. Following the patent expiry of the brand 
BuTrans and the entry of the originator company own 
branded generic Butec in February 2016 and competitor 
companies’ generics Reletrans, Panitaz and non-branded 
generic buprenorphine (in September 2016), Sevodyne, 
Bupramyl and Busiete (in 2017), the market share of 
these agents changed dramatically. Butec started to gain 
market share although gradually between February and 
August 2016 and achieved 38% of the market by August 
2016. In contrast, non-branded generic buprenorphine 
gained a high market share (58%) on entry in September 
2016 (figure 1). Following an initial fall when competitor 
generics were launched in September 2016, the market 
share of Butec started to increase again and achieved 78% 
of the market by January 2018. The utilisation of BuTrans 
(originator brand) and non-branded generic buprenor-
phine fell during this period and the other generics 
gained little market share since launch (figure 1).
expenditure on lDtb patches
Regression analysis indicated that the overall monthly 
expenditure on LDTB patches decreased significantly 
(p>0.001) by an average of 1.11% per month (95% CI 
−0.82 to −1.71) from £3 868 890 ($5 859 836) in February 
2015 to £3 321 780 ($4 327 013) in January 2018. Figure 2 
shows that before September 2016, the overall primary 
care expenditure on LDTB patches follows the utilisation 
pattern. Post-September 2016, the expenditure decreased 
in spite of the increased utilisation of LDTB patches.
segmented regression of interrupted time series
Pre-Butec entry market phase (February 2015–January 2016)
The trend of interrupted time series analysis (table 2) 
indicates that the monthly utilisation of the brand 
BuTrans rose significantly before the introduction of 
Butec in February 2016, as shown by the change in slope 
β1 (table 2).
Post-Butec entry market phase market phase (February 2016–
August 2016)
The change in trend (β3) showed a statistically significant 
increase in utilisation of Butec patches and a significant 
negative impact on the utilisation of the brand BuTrans 
(table 2 and figure 1). The level (β2) of the brand BuTrans 
did not change significantly (table 2).
Figure 2 Expenditure on low-dose transdermal 
buprenorphine patches in England primary care between 
2015 and 2018. LDTB, low-dose buprenorphine.
Figure 1 Utilisation of low-dose transdermal buprenorphine 
patches in England primary care between 2015 and 
2018. LDTB, low-dose buprenorphine. 
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Post-other generic LDTB entry market phase market phase 
(September 2016–January 2018)
Once generic LDTB (other than Butec) were available, 
there was a significant decrease in the level of utilisation 
(β4) of BuTrans and Butec. The trend of utilisation (β5) 
of BuTrans and non-branded generic buprenorphine 
decreased significantly during this phase. In contrast, the 
trend of utilisation of Butec, Reletrans, Panitaz, Sevodyne 
Bupramyl and Busiete increased during this phase.
The change in the trend was significant for Butec, 
Reletrans, Panitaz and Sevodyne, although the actual 
utilisation of the later three generics were relatively low 
compared with Butec (table 2 and figure 1).
Table 3 shows that between February and August 2016, 
when Butec was the only branded generic LDTB in the 
market, there was a saving of £705 917 ($924 751) in 
primary care in England.
A hypothetical model (figure 3) was built to simulate 
the entry of all generic LDTB at the same time, between 
February and August 2016, to determine the potential 
savings that could have been achieved if they had all 
entered the market in February 2016. Table 3 shows that 
if all generic LDTB patches had entered the market at the 
same time with Butec, savings of £1 202 132 ($1 574 792) 
could have been achieved. This represents a further £0.5 
($0.655) million savings that was lost to the NHS over this 
6-month period.
DIsCussIOn
In 2016/2017, the NHS spent £15.4 billion on medicines 
in both primary and secondary care; only 28% of this 
expenditure was on generic medicines.19 The pharmaceu-
tical market is lucrative and competitive, and the intro-
duction of generic alternatives poses a financial threat to 
the branded drug industry. The market share of branded 
medicines is protected via patent.25 At the time of patent 
expiration, innovator firms often attempt to extend the 
patent life of their products, to maintain market exclusivity 
and avoid losing profit. Several strategies have been used 
to combat generic competition, including changing the 
dosage form, modified release formulation, combination 
products, alteration to the next generation of metabolites 
or analogues or extending licensed indication, so-called 
‘evergreening’ strategies.26–30 A more recent method of 
protecting market share is for innovator firms to acquire 
generics operations or produce their own generics, often 
known as ‘flanking generics’.25 This strategy enables the 
entry of a generic version to the market without any loss 
in the market share, making the market less attractive to 
the entry of other rivals, since they would have to compete 
with greater discounts to make their product attractive. 
Napp appears to employed such a strategy by launching 
their own generic first and then appealed an infringe-
ment of its patent by Sandoz in the UK patent court, thus 
delaying entry of other competitors.6
This study aimed to understand the impact of the 
delayed the entry of generic LDTB patches in England. T
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Our study is the first to calculate the impact of delayed 
entry of generic LDTB patches other than Butec and esti-
mating the potential savings lost to the NHS realised from 
this delay in England.
Two different pricing strategies appeared to have 
been implemented by the innovator company following 
the launch of ‘Butec’. With the higher unit price of the 
originator brand, BuTrans, was unchanged to maintain 
revenue through brand loyalty. The branded generic, 
Butec, was originally discounted by 15% compared with 
BuTrans. Once the patent case was successfully appealed 
and other generic LDTB entered the market, the price fell 
sharply to 50% of the originator brand and matched the 
price of the newly launched generics (table 1). The time 
of entry of Butec as a first generic LDTB, being identical 
to the originator brand (BuTrans) and its lower price 
were responsible for the innovator company retaining 
91% of the market.
Market genericisation and the price reduction due to 
competition for market share between these were respon-
sible for the significant reduction in the overall expen-
diture on LDTB in England primary care despite the 
significant increase in the utilisation (figure 2).
Segmented regression analysis was used to identify the 
impact of marketing of Butec and other generic LDTB 
on the prescribing of the brand originator BuTrans and 
the impact of the marketing of Butec on the utilisation of 
other generic LDTB in primary care in England. Before 
the patent expiry of BuTrans and the entry of Butec, 
the utilisation of BuTrans was increasing significantly 
(table 2). The slow market growth of Butec during the 
first 3 months of entry was responsible for non-significant 
change in the level of utilisation of BuTrans (table 2). 
After this lag period, Butec started to replace BuTrans in 
the market, as the trend of utilisation of Butec exceeded 
BuTrans trend. This lag period might be due to the time 
it took for Butec to be included in the clinical commis-
sioning group (CCG) formularies and prescribing soft-
ware such as EMIS, as well as the time for awareness 
among prescribers to the availability of Butec.
Once other generic LDTB patches were available, other 
than Butec, the only generic to gain market traction was 
non-branded generic buprenorphine, which achieved 
Table 3 Expected, actual and hypothetical savings from the entry of generic LDTB patches
Expected 
expenditure on 
BuTrans
Actual 
expenditure on 
Butec
Hypothetical 
expenditure on 
generic LDTB 
patches
Case 1 
scenario.
Actual savings 
from the entry 
of Butec
Case 2 scenario.
Expected 
savings from 
the entry of 
generic LDTB
Hypothetical 
savings from the 
entry of generic 
LDTB compared 
with the entry of 
Butec only
February 2016 £18 555 £16 774 £17 701 £1781 £854 –£927
$24 307 $21 973 $23 188 $2333 $1118 –$1214
March 2016 £10 916 £9972 £10 307 £944 £609 –£335
$14 300 $13 063 $13 502 $1236 $797 –$438
April 2016 £58 716 £53 014 £47 654 £5702 £11 062 £5360
$76 917 $69 448 $62 426 $7469 $14 491 $7021
May 2016 £366 998 £332 344 £285 061 £34 653 £81 937 £47 284
$480 767 $435 370 $373 429 $45 395 $107 337 $61 942
June 2016 £849 529 £697 845 £640 097 £151 683 £209 432 £57 749
$1 112 882 $914 176 £838 527 $1 98 704 $274 355 $75 651
July 2016 £1 342 649 £1 118 900 £979 928 £2 23 747 £362 721 £138 974
$1 758 870 $1 465 759 $1 283 705 $2 93 108 $475 164 $182 055
August 2016 £1 824 602 £1 537 199 £1 289 085 £287 402 £535 517 £248 115
$2 390 228 $2 013 730 $1 688 701 $376 496 $701 527 $325 030
Overall £4 471 965 £3 766 048 £3 269 833 £705 917 £1 202 132 £496 220
$5 858 274 $4 933 522 $4 283 481 $924 751 $1 574 792 $650 048
LDTB, low-dose buprenorphine.
Figure 3 Hypothetical model for the market share if all 
generic LDTB entered in February 2016. LDTB, low-dose 
buprenorphine.
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58% of the market at the time of entry. Since LDTB was 
eligible for automatic substitution in primary care, there-
fore, when LDTB prescribed generically or by non-pro-
prietary name, it is possible that the non-branded generic 
buprenorphine may have been dispensed. Interestingly, 
a similar situation has been reported with pregabalin 
during a period of patent litigation between 2015 and 
2017, in which the generic pregabalin did not result in 
cost savings to the NHS, despite gaining more than half 
of the market. This is due to the reimbursement price for 
this generic being similar to the brand Lyrica.31 Smyth et 
al32 suggested that the generic pregabalin was priced in 
this way, because the UK Department of Health did not 
wish to recategorise pregabalin as generic while the orig-
inator brand Lyrica second patent (pain patent) was still 
being asserted by Pfizer.32 This introduction of generic 
LDTB (other than Butec) was responsible for an imme-
diate decline in the level of utilisation of BuTrans and 
Butec (table 2).
The price flexibility strategy adopted for Butec was 
probably responsible for the recovery in the uptake of this 
product and the decline in the utilisation of non-branded 
generic buprenorphine where a price did not change 
in response to the competition (table 1). In October 
2017, the Care Quality Commission recommended that 
buprenorphine patches should be prescribed by brand 
name rather than by non-proprietary name, to avoid any 
confusion due to the high incidence of actual harm from 
buprenorphine transdermal patches.33 34 At the same 
time, the non-branded generic buprenorphine was with-
drawn from the UK market. Butec captured a significant 
market share and helped the company to retain 91% of 
LDTB patches market. This market share was then main-
tained with the Care Quality Commission recommenda-
tion to prescribe by brand name. In addition to price 
flexibility strategy, prescriber and commissioner famil-
iarity with Butec as the only generic LDTB patch available 
from February to August 2016, may also have contributed 
to this gain in market share. For example, a number of 
CCGs such as Calderdale, Greater Glasgow and Clyde, 
Hambleton, Richmondshire and Whitby, Oxfordshire, 
Sheffield and Sunderland Medicines Optimisation Group 
recommended Butec as a brand of choice of LDTB 
patches in primary care, replacing BuTrans since it is 
identical in formulation to BuTrans and strength (5, 10, 
15 and 20 mcg/hr) and also lower in price, thus offering 
significant savings.35–40
Two case scenarios were modelled, to determine the 
savings from the entry of Butec only between February 
and August 2016, and the potential savings which could 
have been achieved if all generic LDTB patches had 
entered the market at the same time.
The results of these models showed that the introduc-
tion of all generics LDTB at the same time of Butec could 
have delivered a higher cost saving to the NHS (£1.2 
($1.57) million) compared with (£0.7 ($0.92) million) as 
a result of the entry of Butec alone (table 3). These lost 
savings to the NHS are funds wasted directly impacting 
patients and ultimately tax payers which could be rein-
vested in other services for the patients. Previous work 
has established that when all other factors are equal, 
price strongly influences prescribing.41 42 Thus, as Butec 
was identical to BuTrans in all but name (manufactured 
on the same line and so on), then it was an attractive, less 
expensive alternative to BuTrans. Although about £0.5 
($0.65) million in potential savings was lost to the NHS, 
the savings lost were unlikely to have been greater as the 
strategy of increased price reduction of Butec, which 
occurred at the entry of generic competitors, would 
most likely have occurred earlier and still restricted the 
market growth of competitor generics. The lost savings 
from the delayed entry of generic LDTB patches is much 
less than savings lost from the prolongation of the patent 
of Lyrica, which has been estimated to be approximately 
£500 million due to the longer duration of litigation 
and greater utilisation of pregabalin in comparison with 
LDTB patches.29 Our study and the work done by Croker 
et al support the estimate that a more cost effective policy 
could save the NHS over £1 billion per year.31 43
The LDTB market did not behave as would be expected 
following patent expiry and introduction of generics. 
For example, following the patent expiry of atorvastatin 
in 2011, the price of the brand (Lipitor) decreased by 
50% and generic atorvastatin were priced at 25% of this 
brand price, which resulted in significant cost savings to 
the NHS.30 In the case of LDTB patches, the legal chal-
lenge by the innovator company resulted in a 6-month 
delay in the launch of competitor generics. This delay 
allowed the innovator own generic to gain significant 
market share which was subsequently maintained when 
other competitor generics launched 6 months later. Our 
model suggests that the 6-month delay resulted in a 
potential £0.5 ($0.65) million worth of savings being lost 
to the NHS. It is unlikely that the NHS has lost signifi-
cantly more savings due to the late entry of all generic 
LDTB patches since their introduction has resulted in the 
manufacturer of leading generic LDTB patch, Butec, to 
reduce its price significantly. Our results are in line with 
Duerden and Hughes study results that suggested that 
switching to generics are dependent on the availability 
and timing of introduction of generic products.20
Our study has some limitations. The model built did 
not consider the impact of the entry of multiple generics 
on the market share and the price of the originator 
brand, since the entry of large number of generics (ie, 
competitors) would be expected to be associated with a 
sharp price reduction and/or market share of the origi-
nator brand. In the case of LDTB patches, this impact was 
prevented by the originator company producing its own 
generic and delaying the entry of competitor generics. 
Furthermore, the prices used in this analysis were the stan-
dard list prices of the drug and not including dispensing 
costs. The savings listed and relative costings are based 
on net ingredient cost, but the average discount deduc-
tion made to chemist contractors of approximately 8% 
may mean that the actual costs are different. The case 
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scenario two assumed that the market share of generics 
would behave in a similar way to Butec in scenario 1. 
It is possible that the market share of the various prod-
ucts may have reacted differently with the availability of 
multiple generics in February 2016. A non-uniform linear 
price change per mg between all strengths of the patches 
exists, therefore, the average cost per mg for the most 
frequently prescribed strength was chosen.
COnClusIOn
The entry of Butec following the patent expiry of BuTrans 
was associated with apparent cost saving. More cost 
savings could have been achieved if other generic LDTB 
entered the market at the same time to drive competi-
tion between rivals. Patent protection strategies which 
delayed the entry of multiple generics was responsible for 
the reduced cost savings to the NHS in England but later 
minimised by an aggressive price reduction strategy.
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